TORONTO, ONTARIO--(Marketwired - Oct. 29, 2013) -
Editors Note: There is a photo associated with this press release.
For the first time in Canada, infertile couples will have access to state-of-the-art technology with the installation of the EmbryoScope™, a revolutionary and clinically-tested system that uses time-lapse imaging to continuously monitor embryo development and more accurately detect those embryos most likely to implant in patients undergoing IVF (In Vitro Fertilization). The EmbryoScope™ has been installed in Toronto's renowned CReATe Fertility Centre.
"We are thrilled to be housing Canada's only EmbryoScope™ which honours our commitment to exploring every possible resource that will aid our patients in achieving their dream of becoming parents," comments Dr. Clifford Librach, Founder and Director, CReATe Fertility Centre. "With the use of the EmbryoScope™, we will be able to relieve our patients of some of the emotional and financial burdens often associated with infertility. This system truly represents a major breakthrough in our field."
Simply put, the EmbryoScope™ allows closer monitoring and more ideal and precise assessments of embryonic development, which translates into more successful pregnancies with fewer IVF treatments. Using a Time-lapse system, a movie is generated for each embryo, allowing embryologists to monitor various characteristics of their development over the entire incubation period, while maintaining optimum incubation conditions in a state-of-the-art incubator.
"The opportunity to closely monitor all stages of embryonic development enhances our ability to select the best embryo for transfer, increasing the chances of pregnancy, while reducing the risk of multiple pregnancies. The technology also allows us to collect a tremendous amount of critical data on how normal and abnormal human embryos develop, making it a very valuable research tool," says Dr Librach.
The EmbryoScope™ technology was developed by Danish company Unisense FertiliTech A/S and is currently the only time-lapse system with FDA 510(k) clearance and is CE marked as a Class IIa medical device. The system has been adopted by clinics in more than 35 countries and used in more than 80,000 treatments worldwide with reported results of reduced miscarriages and improved pregnancy rates. At the recent American Society for Reproductive Medicine conference, a relative decrease in early pregnancy loss of 30% compared to standard IVF treatment was reported as well as a relative uplift in pregnancy rates of 40%.
Approximately 1 in 6 Canadian couples suffer with infertility and that number continues to rise. With emerging research and access to ground-breaking technologies like the EmbryoScope™ Time-lapse system, individuals suffering from infertility may now take one more baby step towards realizing their dreams.
About the CReATe Fertility Centre
CReATe Fertility Centre, founded by Dr Clifford Librach in 1991, is one of the most technologically advanced fertility centres in the world, providing state of the art fertility treatment for couples experiencing infertility. CReATe Fertility Centre's team of doctors, which also includes Dr. Ari Baratz, Dr. Karen Glass and Dr. Prati Sharma are affiliated with the University of Toronto, The Women's College Hospital and the Sunnybrook Health Sciences Centre. CReATe also works with a number of affiliated satellite physicians. CReATe is conveniently located in downtown Toronto, close to two TTC subway stations, at 790 Bay Street, Suite 1100. For further information or to make an appointment, please call 416-323-7727, fax 416-323-7334 or email firstname.lastname@example.org.
About Unisense FertiliTech A/S:
Unisense FertiliTech A/S was founded in 2003 to develop technology to improve human embryo assessment in assisted reproduction. Unisense FertiliTech has developed, and manufactures the EmbryoScope™ - a unique Time-lapse system facilitating improved IVF treatment, flexible work routines and effective communication through comprehensive documentation of embryo development and evolving improvements in selection. The System is FDA 510(k) cleared and CE marked as a Class II medical device. Unisense Fertilitech A/S' mission is to help infertile couples achieve their dream of parenthood through development of novel technology, quantification and digitized documentation. For more information, visit www.fertilitech.com.
To view the photo associated with this press release, please visit the following link: http://www.marketwire.com/library/20131028-CFCL.jpg.